文献速递药疹与重症皮肤不良反应银屑病与炎症性皮肤病自身免疫性与大疱性皮肤病

免疫检查点抑制剂相关皮肤不良事件

Immune checkpoint inhibitor-related dermatologic adverse events.
PubMed 文献 · J Am Acad Dermatol · 2020-05-23

免疫检查点抑制剂是晚期恶性肿瘤治疗的重要支柱,但非特异性免疫激活可导致免疫相关不良事件,其中皮肤及附属器最常受累。皮肤免疫相关不良事件包括斑丘疹、瘙痒、银屑病样和苔藓样皮疹等,多在初始给药后6周内出现。轻中度皮疹用局部皮质类固醇,重度加全身皮质类固醇,4级需停用免疫治疗;大疱性类天疱疮样皮疹3-4级可加用利妥昔单抗。

要点

  • 斑丘疹多在免疫检查点抑制剂首次给药后6周内出现。
  • 1-2级皮疹用局部皮质类固醇,3级加全身皮质类固醇,4级停用免疫治疗。
  • 大疱性类天疱疮样皮疹3-4级可加用利妥昔单抗,色素减退仅需光防护。

核心结论

  • 皮肤及附属器是免疫检查点抑制剂相关免疫不良事件最常累及的靶点。
  • 皮肤免疫相关不良事件包括斑丘疹、瘙痒、银屑病样和苔藓样皮疹等,多在治疗早期出现。
  • 根据皮疹分级采用局部或全身皮质类固醇,4级需停用免疫治疗。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • 斑丘疹多在免疫检查点抑制剂首次剂量后6周内出现。
  • 大疱性类天疱疮样皮疹、白癜风样色素减退/脱失和银屑病样皮疹更常归因于PD-1/PD-L1抑制剂。
  • Stevens-Johnson综合征等严重皮肤免疫相关不良事件虽罕见,但与检查点阻断相关,需住院和紧急皮肤科会诊。

关键数值与推荐

  • 轻中度(1-2级)皮疹使用局部皮质类固醇。
  • 重度(3级)皮疹加用全身皮质类固醇。
  • 4级皮疹停用免疫治疗。
  • 大疱性类天疱疮样皮疹3-4级可加用利妥昔单抗。
  • 银屑病样皮疹除局部皮质类固醇外,可用维生素D3类似物、窄谱中波紫外线光疗、维A酸类或免疫调节生物制剂。

临床怎么用

  • 按皮疹分级选择局部或全身皮质类固醇,4级停用免疫治疗。
  • 大疱性类天疱疮样皮疹3-4级可加用利妥昔单抗。
  • 色素减退/脱失无需特殊皮肤治疗,仅需光防护。
  • 银屑病样皮疹可选用维生素D3类似物、窄谱UVB、维A酸类或生物制剂。
  • 严重皮肤不良反应需住院并紧急皮肤科会诊。

局限性

  • 摘要未报告检索范围、样本量或具体研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors have emerged as a pillar in the management of advanced malignancies. However, nonspecific immune activation may lead to immune-related adverse events, wherein the skin and its appendages are the most frequent targets. Cutaneous immune-related adverse events include a diverse group of inflammatory reactions, with maculopapular rash, pruritus, psoriasiform and lichenoid eruptions being the most prevalent subtypes. Cutaneous immune-related adverse events occur early, with maculopapular rash presenting within the first 6 weeks after the initial immune checkpoint inhibitor dose. Management involves the use of topical corticosteroids for mild to moderate (grades 1-2) rash, addition of systemic corticosteroids for severe (grade 3) rash, and discontinuation of immunotherapy with grade 4 rash. Bullous pemphigoid eruptions, vitiligo-like skin hypopigmentation/depigmentation, and psoriasiform rash are more often attributed to programmed cell death-1/programmed cell death ligand-1 inhibitors. The treatment of bullous pemphigoid eruptions is similar to the treatment of maculopapular rash and lichenoid eruptions, with the addition of rituximab in grade 3-4 rash. Skin hypopigmentation/depigmentation does not require specific dermatologic treatment aside from photoprotective measures. In addition to topical corticosteroids, psoriasiform rash may be managed with vitamin D3 analogues, narrowband ultraviolet B light phototherapy, retinoids, or immunomodulatory biologic agents. Stevens-Johnson syndrome and other severe cutaneous immune-related adverse events, although rare, have also been associated with checkpoint blockade and require inpatient care as well as urgent dermatology consultation.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020. PMID: 32454097. doi:10.1016/j.jaad.2020.03.132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。